Published in Mult Scler on October 15, 2008
Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One (2011) 1.02
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord (2012) 0.91
Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol (2015) 0.90
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases (2015) 0.88
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol (2014) 0.87
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate. BMC Neurol (2015) 0.81
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon. BMC Neurol (2015) 0.80
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey. Neurol Ther (2014) 0.78
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol (2011) 0.78
Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients. Neurol Ther (2017) 0.76
(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis. Int J Mol Sci (2017) 0.75
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. Int J MS Care (2016) 0.75
Improving outcomes in multiple sclerosis through early diagnosis and effective management. Prim Care Companion CNS Disord (2012) 0.75
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Int J Mol Sci (2015) 0.75
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA (1989) 5.66
Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet (2001) 5.28
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90
Natural history of HIV infection. AIDS (1989) 3.75
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology (2008) 3.68
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS (1994) 3.67
Construction of YAC-based mammalian artificial chromosomes. Nat Biotechnol (1998) 3.55
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
Risk factors for AIDS and HIV seropositivity in homosexual men. Am J Epidemiol (1987) 2.62
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Comparison of custom and prefabricated orthoses in the initial treatment of proximal plantar fasciitis. Foot Ankle Int (1999) 2.37
The impact of HIV on chronic kidney disease outcomes. Kidney Int (2007) 2.22
Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.17
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology (2011) 2.02
Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology (2011) 1.99
Hormonal risk factors in testicular cancer. A case-control study. Am J Epidemiol (1986) 1.97
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88
T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol (1995) 1.78
Prehospital stability of diazepam and lorazepam. Am J Emerg Med (1999) 1.72
Sensitivity of treponemal tests for detecting prior treated syphilis during human immunodeficiency virus infection. J Infect Dis (1990) 1.67
Mortality associated with mode of presentation in the acquired immune deficiency syndrome. J Natl Cancer Inst (1984) 1.59
The underreporting of deaths of American Indian children in California, 1979 through 1993. Am J Public Health (1997) 1.58
Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med (2000) 1.56
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 1.56
Role of the sigma 70 subunit of Escherichia coli RNA polymerase in transcription activation. J Mol Biol (1994) 1.54
Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis (2000) 1.51
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler (2012) 1.51
Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology (2008) 1.50
Mammalian artificial chromosome formation from circular alphoid input DNA does not require telomere repeats. Hum Mol Genet (2000) 1.44
Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest (2000) 1.43
Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology (1997) 1.43
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology (1999) 1.42
Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology (1994) 1.37
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain (2008) 1.37
Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology (2000) 1.32
Lower genital tract infections among HIV-infected and high-risk uninfected women: findings of the Women's Interagency HIV Study (WIHS). Sex Transm Dis (1999) 1.27
Chance, concurrence, and clustering. Analysis of reviewers' recommendations on 1,000 submissions to the Journal of Clinical Investigation. J Clin Invest (1994) 1.27
Consequences of worksite hypertension screening. Differential changes in psychosocial function. Am J Med (1986) 1.25
Assay of centromere function using a human artificial chromosome. Chromosoma (1998) 1.20
Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Blood (1999) 1.20
Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol (1994) 1.18
Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. Radiology (2000) 1.18
A serial study of new MS lesions and the white matter from which they arise. Neurology (1998) 1.17
Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood (2001) 1.16
Do we truly see what we think we see? The role of cognitive bias in pathological interpretation. J Pathol (2008) 1.15
Effects of primary care coordination on public hospital patients. J Gen Intern Med (2000) 1.15
Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood (2001) 1.14
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol (1996) 1.14
Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV study. AIDS (2000) 1.13
Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology (1994) 1.10
A human DAZ transgene confers partial rescue of the mouse Dazl null phenotype. Proc Natl Acad Sci U S A (1999) 1.10
Immune activation markers and AIDS prognosis. AIDS (1991) 1.09
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ (1991) 1.08
Risk of low birth weight infants among black and white parents. Obstet Gynecol (1998) 1.06
Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology (2009) 1.04
Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. Br J Ophthalmol (1996) 1.02
Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis (1989) 1.01
Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology (1998) 1.01
Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology (2009) 1.00
Human T cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis (1991) 0.99
Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology (1994) 0.98
Lymphocyte subset analysis to predict progression to AIDS in a cohort of homosexual men in San Francisco. Clin Immunol Immunopathol (1989) 0.98
Distinct functional properties of highly purified hematopoietic stem cells from mouse strains differing in stem cell numbers. Blood (2000) 0.98
1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler (2000) 0.96
Are initial demyelinating event recovery and time to second event under differential control? Neurology (2006) 0.96
Cofactors for HIV disease progression in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr (2001) 0.96
Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology (2010) 0.95
Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol (2000) 0.95
Treatment of pediatric multiple sclerosis and variants. Neurology (2007) 0.95
Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count. J Dent Res (2004) 0.95
The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry (2008) 0.94
Weight history and hypertension. J Clin Epidemiol (1988) 0.94
Utilization of TCD screening for primary stroke prevention in children with sickle cell disease. Neurology (2009) 0.92
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology (2003) 0.92
Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology (1994) 0.92
A hybrid sigma subunit directs RNA polymerase to a hybrid promoter in Escherichia coli. J Mol Biol (1995) 0.91
Time of exposure and risk of HIV infection in homosexual partners of men with AIDS. Am J Public Health (1988) 0.91
Changes in bone resorption during the menstrual cycle. J Bone Miner Res (1999) 0.90
Complete nucleotide sequences of the nuclear pseudogenes for cytochrome oxidase subunit I and the large mitochondrial ribosomal RNA in the sea urchin Strongylocentrotus purpuratus. J Mol Biol (1986) 0.89
Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells. Blood (2000) 0.89
Influence of gender on cardiovascular mortality in acute myocardial infarction patients with high indication for coronary angiography. Circulation (1997) 0.88
An annotated bibliography of methods for analysing correlated categorical data. Stat Med (1992) 0.88
The impact of surgical complications after liver transplantation on resource utilization. Arch Surg (1997) 0.88
Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol (1999) 0.87
Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. Leukemia (1999) 0.87
Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry (2008) 0.87
Characteristic features of actinomycin D-induced paw inflammation of the rat. Exp Mol Pathol (1975) 0.87
Consequences of worksite hypertension screening. Changes in absenteeism. Hypertension (1987) 0.86